Title: AN IMPROVED PROCESS FOR THE PREPARATION OF PAZOPANIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

Abstract: The present invention relates to an improved process for the preparation of pazopanib or a pharmaceutically acceptable salts thereof. The present invention also relates to novel polymorphic Forms of pazopanib hydrochloride, and its intermediates thereof.
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER
A61K31/517, C07D403/12 Version=2.015.01

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A 61 K, C07 D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic database consulted during the international search (name of data base and, where practicable, search terms used)
PATSEER, IPO INTERNAL DATABASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y</td>
<td>WO 03/106416 A2 (SMITHKLINE BEECHAM CORPORATION) 24/12/2003 see page-45 example-4, page-52 and example-1</td>
<td>1-253</td>
</tr>
<tr>
<td>A</td>
<td>WO 03/106416 A2 (SMITHKLINE BEECHAM CORPORATION) 24/12/2003 abstract and claims</td>
<td>92</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:
  "A" document defining the general state of the art which is not considered to be of particular relevance
  "E" earlier application or patent published on or after the international filing date
  "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
  "O" document referring to an oral disclosure, use, exhibition or other means
  "P" document published prior to the international filing date but later than the priority date claimed

"I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&" document member of the same patent family

Date of the actual completion of the international search 18-06-2015
Date of mailing of the international search report 18-06-2015

Name and mailing address of the ISA/
Indian Patent Office
Plot No. 31, Sector 14, Dwarka, New Delhi-110075
Facsimile No.

Authorized officer
Md Atiquullah
Telephone No. +91-1125300200

Form PCT/ISA/210 (second sheet) (January 2015)
INTERNATIONAL SEARCH REPORT

Box No. II  Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
   because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
   because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:
   because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III  Observations where unity of invention is Sacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. Claims 1 - 28 and 92 (in part)
   The subject matter of the claims 1 - 28 discloses improved processes for preparation of pazonib or a pharmaceutically acceptable salt of Formula A - 1.

2. Claims 29 - 34 and 92 (in part)
   The subject matter of the claims 29 - 34 discloses crystalline Form L1 of pazonib hydrochloride and processes for preparing pazonib hydrochloride Form L1.

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.

3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims. It is covered by claims Nos. 1 - 28 and 92 (in part).

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

☐ No protest accompanied the payment of additional search fees.
Continuation of Observations where unity of invention is lacking (Box III)

3. Claims 35-39 and 92 (in part)
   The subject matter of the claims 35-39 discloses crystalline Form L2 of Pazopanib hydrochloride and process for preparing Pazopanib hydrochloride Form L2.

4. Claims 40-44 and 92 (in part)
   The subject matter of the claims 40-44 discloses crystalline Form L3 of Pazopanib hydrochloride and process for preparing Pazopanib hydrochloride Form L3.

5. Claims 45-58 and 92 (in part)
   The subject matter of the claims 45-48 discloses crystalline Form L4 of Pazopanib hydrochloride and process for preparing Pazopanib hydrochloride Form L4.

6. Claims 49-52 and 92 (in part)
   The subject matter of the claims 49-52 discloses crystalline Form L5 of Pazopanib hydrochloride and process for preparing Pazopanib hydrochloride Form L5.

7. Claims 53-56 and 92 (in part)
   The subject matter of the claims 53-56 discloses crystalline Form L6 of Pazopanib hydrochloride and process for preparing Pazopanib hydrochloride Form L6.

8. Claims 57-60 and 92 (in part)
   The subject matter of the claims 57-60 discloses crystalline Form L7 of Pazopanib hydrochloride and process for preparing Pazopanib hydrochloride Form L7.

9. Claims 61-65 and 92 (in part)
   The subject matter of the claims 61-65 discloses crystalline Form L8 of Pazopanib hydrochloride and process for preparing Pazopanib hydrochloride Form L8.

10. Claims 66-70 and 92 (in part)
The subject matter of the claims 66-70 discloses crystalline Form L9 of Pazopanib hydrochloride and process for preparing Pazopanib hydrochloride Form L9.

11. Claims 71-73 and 92 (in part)

The subject matter of the claims 71-73 discloses crystalline Form klof N-(2 chloropyrimidin-4-yl)-N-2, 3-trimethyl-2H-indazol-6-amine (Formula III) and the process for preparation of said form k1.

12. Claims 74-77 and 92 (in part)

The subject matter of the claims 74-77 discloses crystalline Form k2of N-(2 chloropyrimidin-4-yl)-N-2, 3-trimethyl-2H-indazol-6-amine (Formula III) and the process for preparation of said form k2.

13. Claims 78-80 and 92 (in part)

The subject matter of the claims 78-80 discloses crystalline Form k3of N-(2 chloropyrimidin-4-yl)-N-2, 3-trimethyl-2H-indazol-6-amine (Formula III) and the process for preparation of said form k3.

14. Claims 81-84 and 92 (in part)

The subject matter of the claims 81-84 discloses crystalline Form k4of N-(2 chloropyrimidin-4-yl)-N-2, 3-trimethyl-2H-indazol-6-amine (Formula III) and the process for preparation of said form k4.

15. Claims 85-91 and 92 (in part)

The subject matter of the claims 85-91 discloses a process preparation of pazopanib hydrochloride Form-1.
<table>
<thead>
<tr>
<th>Citation</th>
<th>Pub. Date</th>
<th>Family</th>
<th>Pub. Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>EP 1343782 A1</td>
<td>17-09-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 7105530 B2</td>
<td>12-09-2006</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 2002059110 A1</td>
<td>01-08-2002</td>
</tr>
<tr>
<td>WO 2003106416 A2</td>
<td>24-12-2003</td>
<td>CA 2489648 A1</td>
<td>24-12-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1515955 A2</td>
<td>23-03-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 20060252943 A1</td>
<td>09-11-2006</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 2003106416 A3</td>
<td>06-05-2004</td>
</tr>
</tbody>
</table>